Rein Therapeutics, Inc. Deferred Offering Costs
Rein Therapeutics, Inc. (RNTX) had Deferred Offering Costs of $2.22 million as of 2017-06-30, per its 10-Q filed 2017-08-10.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredOfferingCosts · last filed 2017-08-10
- 2017-06-30: Deferred Offering Costs $2.22M.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-06-30 | $2.22M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |